Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands.

Mei Zhu,Biao Dong,Guo-Ning Zhang,Ju-Xian Wang,Shan Cen,Yu-Cheng Wang

DOI: https://doi.org/10.1016/j.bmcl.2019.03.049

IF: 2.94

2019-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:IC50 = 43 nM, 42 nM and 68 nM (in vitro).

What problem does this paper attempt to address?

Preliminary SAR and Biological Evaluation of Potent HIV-1 Protease Inhibitors with Pyrimidine Bases As Novel P2 Ligands to Enhance Activity Against DRV-resistant HIV-1 Variants

Mei Zhu,Ling Ma,Huiyu Zhou,Biao Dong,Yujia Wang,Zhen Wang,Jinming Zhou,Guoning Zhang,Juxian Wang,Chen Liang,Shan Cen,Yucheng Wang

DOI: https://doi.org/10.1016/j.ejmech.2019.111866

IF: 7.088

2020-01-01

European Journal of Medicinal Chemistry

Abstract:Introducing pyrimidine bases, the basic components of nucleic acid, to P2 ligands might enhance the potency of Human Immunodeficiency Virus-1 (HIV-1) protease inhibitors because of the carbonyl and amino groups promoting the formation of extensive hydrogen bonding interactions. In this work, we provide evidence that inhibitor 10e, with N-2-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl) acetamide as the P2 ligand and a 4-methoxylphenylsulfonamide as the P2' ligand, displayed remarkable enzyme inhibitory and antiviral activity, with the IC50 2.53 nM in vitro and a promising inhibition ratio with 68% against wild-type HIV-1 in vivo, with low cytotoxicity. This inhibitor also exhibited appreciable antiviral activity against DRV-resistant HIV-1 variants, which was of great value for further study. (C) 2019 Elsevier Masson SAS. All rights reserved.
Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1 ligands

Mei Zhu,Ling Ma,Biao Dong,Guoning Zhang,Juxian Wang,Jinming Zhou,Shan Cen,Yucheng Wang

DOI: https://doi.org/10.4155/fmc-2019-0331

2020-01-01

Future Medicinal Chemistry

Abstract:Aim: HIV-1 protease inhibitors regimens suffered from a number of drawbacks, among which, the most egregious issue was the growing emergence of drug-resistant strains. Materials & methods: The design strategy of maximizing the protease active site interactions with the inhibitor, especially promoting extensive hydrogen bonding with the protein backbone atoms, might be in favor of combating drug resistance. A series of HIV-1 protease inhibitors that incorporated enantiomeric isopropanols as the P1 ligands in combination with phenols as the P2 ligands were reported herein. Results: A number of inhibitors displayed potent protease enzyme inhibition activity. In particular, inhibitor 14c showed comparable potency as darunavir with IC50 value of 1.91 nM and activity against darunavir-resistant HIV-1 variants. Conclusion: The new kind of HIV-1 protease inhibitors deserves further study. Graphical abstract
Design, Synthesis, and Biological Evaluation of Novel HIV-1 Protease Inhibitors Containing Pyrrolidine-Derived P2 Ligands to Combat Drug-Resistant Variant

Huiyu Zhou,Ling Ma,Biao Dong,Juxian Wang,Guoning Zhang,Minghua Wang,Shan Cen,Mei Zhu,Qi Shan,Yucheng Wang

DOI: https://doi.org/10.1016/j.ejmech.2023.115389

IF: 7.088

2023-01-01

European Journal of Medicinal Chemistry

Abstract:The design, synthesis, and biological evaluation of a novel series of HIV-1 protease inhibitors containing pyrrolidines with diverse linkers as the P2 ligands and various aromatic derivatives as the P2’ ligands were described. A number of inhibitors demonstrated potent efficacy in both enzyme and cellular assays, as well as relatively low cytotoxicity. In particular, inhibitor 34b with a (R)-pyrrolidine-3-carboxamide P2 ligand and a 4-hydroxyphenyl P2’ ligand displayed exceptional enzyme inhibitory activity with an IC50 value of 0.32 nM. Furthermore, 34b also exhibited robust antiviral activity against both wild-type HIV-1 and drug-resistant variant with low micromolar EC50 values. In addition, the molecular modelling studies revealed the extensive interactions between inhibitor 34b and the backbone residues of both wild-type and drug-resistant HIV-1 protease. These results suggested the feasibility of utilizing pyrrolidine derivatives as the P2 ligands and provided valuable information for further design and optimization of highly potent HIV-1 protease inhibitors.
Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C

Mei Zhu,Huiyu Zhou,Ling Ma,Biao Dong,Jiwei Ding,Jinming Zhou,Juxian Wang,Guoning Zhang,Minghua Wang,Qi Shan,Shan Cen,Yucheng Wang

DOI: https://doi.org/10.1016/j.ejmech.2022.114251

IF: 7.088

2022-01-01

European Journal of Medicinal Chemistry

Abstract:By following up on the design vector of optimizing amine-based HIV-1 protease inhibitors, we have designed and biologically evaluated a novel class of inhibitors with the free nitrogen or sulphone in morpholine cores as P2 ligands in combination with diverse substituted phenylsulfonamide P2′ ligands. As it turns out, a majority of these inhibitors exhibit prominent enzymatic inhibitory activity in low nanomolar ranges with relatively low cytotoxicity. Particularly, inhibitor 1e containing a morpholine carboxamide P2 ligand and a 4-hydroxyphenylsulfonamide P2′ ligand illustrates a robust enzyme inhibitory IC50 value of 90 pM. Furthermore, 1e demonstrates impressive in vivo antiviral activity with EC50 value of 89 nM and a degree of inhibitory potency against the DRV-resistant variant. More importantly, 1e exhibits remarkable activity with EC50 values of 13.59 nM and 8.23 nM against subtype C HIV-1 strains ZM246 and Indie, respectively. Furthermore, the in silico studies provide molecular insights into binding features of inhibitors with HIV-1 protease, and furnish a valuable forecast on further process.
Design and Biological Evaluation of Novel HIV-1 Protease Inhibitors with Isopropanol As P1′ Ligand to Enhance Binding with S1′ Subsite

Mei Zhu,Ling Ma,Biao Dong,Guoning Zhang,Juxian Wang,Jinming Zhou,Shan Cen,Yucheng Wang

DOI: https://doi.org/10.1016/j.bmc.2020.115623

IF: 3.461

2020-01-01

Bioorganic & Medicinal Chemistry

Abstract:Newly designed HIV-1 protease inhibitors that maximize interactions with the protein backbone, especially in the form of hydrogen bonds, may enhance the antiviral potency of these compounds and minimize acquisition of drug-resistant mutations. Herein, we described a series of new HIV-1 PIs containing phenols as the P2 ligands and chiral isopropanol as the P1' ligands, in combination with 4-trifluoromethylphenylsulfonamide or 4-nitrophenylsulfonamide as the P2' ligands. And most of these compounds exhibited nanomolar inhibitory potency. In particular, inhibitors 13c and 13e with 4-trifluoromethylphenylsulfonamide as the P2' ligand and (R) - isopropanol as the P1' ligand, exhibited antiviral IC50, values of 1.64 nM and 2.33 nM, respectively. Furthermore, they also showed remarkable activity against wild-type and DRV-resistant HIV-1 variants that raised the prospect of designing more effective PIs further.
Design, Synthesis and Biological Evaluation of HIV-1 Protease Inhibitors with Morpholine Derivatives As P2 Ligands in Combination with Cyclopropyl As P1' Ligand.

Yue Dou,Mei Zhu,Biao Dong,Ju-Xian Wang,Guo-Ning Zhang,Fan Zhang,Yu-Cheng Wang

DOI: https://doi.org/10.1016/j.bmcl.2020.127019

IF: 2.94

2020-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A series of novel HIV-1 protease inhibitors has been designed and synthesized, which contained morpholine derivatives as the P2 ligands and hydrophobic cyclopropyl as the P1' ligand at the meantime in this study, with the aim of improving the interactions between the active sites of HIV-1 protease and the inhibitors. Twenty-eight compounds were synthesized and assessed, among which inhibitors m18 and m1 exhibited excellent inhibitory effect on the activity of HIV-1 protease with IC50 value of 47 nM and 53 nM, respectively. The molecular modeling of m1 revealed possible hydrogen bondings or van der Waals between the inhibitor and the protease, worthy of in-depth study.
Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants

Ling Ma,Jiajia Wen,Biao Dong,Jinming Zhou,Shangjiu Hu,Juxian Wang,Yucheng Wang,Mei Zhu,Shan Cen

DOI: https://doi.org/10.3390/ijms232214178

2022-11-16

Abstract:With the increasing prevalence of drug-resistant variants, novel potent HIV-1 protease inhibitors with broad-spectrum antiviral activity against multidrug-resistant causative viruses are urgently needed. Herein, we designed and synthesized a new series of HIV-1 protease inhibitors with phenols or polyphenols as the P2 ligands and a variety of sulfonamide analogs as the P2' ligands. A number of these new inhibitors showed superb enzymatic inhibitory activity and antiviral activity. In particular, inhibitors 15d and 15f exhibited potent enzymatic inhibitory activity in the low picomolar range, and the latter showed excellent activity against the Darunavir-resistant HIV-1 variant. Furthermore, the molecular modeling studies provided insight into the ligand-binding site interactions between inhibitors and the enzyme cavity, and they sparked inspiration for the further optimization of potent inhibitors.
Design and Evaluation of Novel Piperidine HIV-1 Protease Inhibitors with Potency Against DRV-resistant Variants

Mei Zhu,Huiyu Zhou,Ling Ma,Biao Dong,Jinming Zhou,Guoning Zhang,Minghua Wang,Juxian Wang,Shan Cen,Yucheng Wang

DOI: https://doi.org/10.1016/j.ejmech.2021.113450

IF: 7.088

2021-01-01

European Journal of Medicinal Chemistry

Abstract:A novel class of HIV-1 protease inhibitors with flexible piperidine as the P2 ligand was designed with the aim of improving extensive interactions with the active subsites. Many inhibitors exhibited good to excellent inhibitory effect on enzymatic activity and viral infectivity. In particular, inhibitor 3a with (R)-piperidine-3-carboxamide as the P2 ligand and 4-methoxybenzenesulfonamide as the P2' ligand showed an enzyme K-i value of 29 pM and antiviral IC50 value of 0.13 nM, more than six-fold enhancement of activity compared to DRV. Furthermore, there was no significant change in potency against DRV-resistant mutations and HIV-1(NL4-3) variant for 3a. Besides, inhibitor 3a exhibited potent antiviral activity against subtype C variants with low nanomole EC50 values. In addition, the molecular modeling revealed important hydrogen bonds and other favorable van der Waals interactions with the backbone atoms of the protease and provided insight for designing and optimizing more potent HIV-1 protease inhibitors. (C) 2021 Elsevier Masson SAS. All rights reserved.
Design and Synthesis of Potent HIV-1 Protease Inhibitors with (S)-Tetrahydrofuran-tertiary Amine-Acetamide As P2−ligand: Structure−activity Studies and Biological Evaluation

Xiaoguang Bai,Zhiheng Yang,Mei Zhu,Biao Dong,Lei Zhou,Guoning Zhang,Juxian Wang,Yucheng Wang

DOI: https://doi.org/10.1016/j.ejmech.2017.05.024

IF: 7.088

2017-01-01

European Journal of Medicinal Chemistry

Abstract:The design, synthesis, and SAR study of a new series of HIV-1 protease inhibitors incorporating stereochemically defined tetrahydrofuran-tertiary amine-acetamide P2-ligand are described. Various substituent effects on the tertiary amine P2-ligand and phenylsulfonamide P2'-ligand were investigated to maximize the ligand-binding site interactions in the protease active site. Most of inhibitors displayed low nanomolar to subnanomolar inhibitory potency. Inhibitor 20e containing N-(S-tetrahydrofuran)-N-(2-methoxyethyl)acetamide as P2-ligand along with 4-methoxylphenylsulfonamide as P2'-ligand displayed the most potent enzyme inhibitory activity (IC50 = 0.35 nM) and remarkably low cytotoxicity (CC50 = 305 1.1M). (C) 2017 Elsevier Masson SAS. All rights reserved.
Piperidine Scaffold As the Novel P2-ligands in Cyclopropyl-Containing HIV-1 Protease Inhibitors: Structure-based Design, Synthesis, Biological Evaluation and Docking Study

Huiyu Zhou,Mei Zhu,Ling Ma,Jinming Zhou,Biao Dong,Guoning Zhang,Shan Cen,Yucheng Wang,Juxian Wang

DOI: https://doi.org/10.1371/journal.pone.0235483

IF: 3.7

2020-01-01

PLoS ONE

Abstract:A series of potent HIV-1 protease inhibitors, containing diverse piperidine analogues as the P2-ligands, 4-substituted phenylsulfonamides as the P2’-ligands and a hydrophobic cyclopropyl group as the P1’-ligand, were designed, synthesized and evaluated in this work. Among these twenty-four target compounds, many of them exhibited excellent activity against HIV-1 protease with half maximal inhibitory concentration (IC50) values below 20 nM. Particularly, compound 22a containing a (R)-piperidine-3-carboxamide as the P2-ligand and a 4-methoxylphenylsulfonamide as the P2’-ligand exhibited the most effective inhibitory activity with an IC50 value of 3.61 nM. More importantly, 22a exhibited activity with inhibition of 42% and 26% against wild-type and Darunavir (DRV)-resistant HIV-1 variants, respectively. Additionally, the molecular docking of 22a with HIV-1 protease provided insight into the ligand-binding properties, which was of great value for further study.
Design and Biological Evaluation of Cinnamic and Phenylpropionic Amide Derivatives As Novel Dual Inhibitors of HIV-1 Protease and Reverse Transcriptase

Mei Zhu,Qi Shan,Ling Ma,Jiajia Wen,Biao Dong,Guoning Zhang,Minghua Wang,Juxian Wang,Jinming Zhou,Shan Cen,Yucheng Wang

DOI: https://doi.org/10.1016/j.ejmech.2021.113498

IF: 7.088

2021-01-01

European Journal of Medicinal Chemistry

Abstract:Upon the basis of both possible ligand-binding site interactions and the uniformity of key residues in active sites, a novel class of HIV-1 PR/RT dual inhibitors was designed and evaluated. Cinnamic acids or phenylpropionic acids with more flexible chain and smaller steric hindrance were introduced into the inhibitors, giving rise to significant improvement in HIV-1 RT inhibitory activity by one or two orders of magnitude, with comparable or even improved potency against PR at the same time, compared with coumarin anologues in our previous studies. Among these inhibitors, 38d displayed a 19-fold improvement in anti-PR activity with IC50 value of 0.081 nM compared to the control DRV. In addition, inhibitor 38c exhibited an excellent anti-RT IC50 value of 0.43 μM, only a 4.7-fold less potent activity than the control EFV. More significantly, the disparate ratio between HIV-1 PR and RT inhibition became more reasonable with ratio of 1: 10.4, just as 37b. Furthermore, the assays on HIV-1 late stage and early stage supported the rationality of designing dual inhibitors. The SAR data as well as molecular modeling studies provided new insight for further optimization of more potent HIV-1 PR/RT dual inhibitors.
Novel HIV-1 Protease Inhibitors with Morpholine As the P2 Ligand to Enhance Activity Against DRV-Resistant Variants

Mei Zhu,Yue Dou,Ling Ma,Biao Dong,Fan Zhang,Guoning Zhang,Juxian Wang,Jinming Zhou,Shan Cen,Yucheng Wang

DOI: https://doi.org/10.1021/acsmedchemlett.0c00043

2020-01-01

ACS Medicinal Chemistry Letters

Abstract:Flexible heterocyclic moieties as the P2 ligands of HIV-1 protease inhibitors may be adapted to the minimally distorted active site of mutations easily and enhance activity against DRV-resistant HIV-1 variants. Herein, the design, synthesis, and biological evaluation of a new series of inhibitors containing morpholine derivatives as the P2 ligands were described, among which, carbamate inhibitor 23a and carbamido inhibitor 27a exhibited almost 4- and 2-fold superior activity with enzyme Ki of 0.092 nM and 0.21 nM, as well as antiviral IC50 values of 0.41 nM and 0.95 nM, respectively, compared to DRV. Besides, they exhibited excellent activity with inhibition of 94% and 91%, respectively. Furthermore, they also showed appreciable antiviral activity against DRV-resistant HIV-1 variants.
Synthesis and Biological Evaluation of Dihydroquinazoline-2-amines As Potent Non-Nucleoside Reverse Transcriptase Inhibitors of Wild-Type and Mutant HIV-1 Strains.

KaiJun Jin,YaLi Sang,Sheng Han,Erik De Clercq,Christophe Pannecouque,Ge Meng,FenEr Chen

DOI: https://doi.org/10.1016/j.ejmech.2019.05.011

IF: 7.088

2019-01-01

European Journal of Medicinal Chemistry

Abstract:A novel series of dihydroquinazolin-2-amine derivatives were synthesized and evaluated for their anti-HIV-1 activity in MT-4 cell cultures. All of the molecules were active against wild-type HIV-1 with EC50 values ranging from 0.61 μM to 0.84 nM. The most potent inhibitor, compound 4b, had an EC50 value of 0.84 nM against HIV-1 strain IIIB, and thus was more active than the reference drugs efavirenz and etravirine. Moreover, most of the compounds maintained high activity (low-micromolar EC50 values) against strains bearing the reverse transcriptase (RT) E138K mutation. Compound 4b had EC50 values of 3.5 nM and 66 nM against non-nucleoside reverse transcriptase inhibitor-resistant strains bearing the RT E138K and RES056 mutations. In enzyme activity assays, compound 4b exhibited an IC50 value of 10 nM against HIV-1 RT. Preliminary SARs and molecular docking studies provide valuable insights for further optimization.
Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

Yue-Ping Wang,Fen-Er Chen,Erik De Clercq,Jan Balzarini,Christophe Pannecouque

DOI: https://doi.org/10.1016/j.bmc.2008.01.039

IF: 3.461

2008-01-01

Bioorganic & Medicinal Chemistry

Abstract:A novel series of 2-arylcarbonylmethylthio-6-arylmethylpyrimidin-4(3H)-ones have been synthesized and evaluated for in vitro anti-HIV activities in MT-4 cells. Most of these new compounds showed moderate to potent activities against wild-type HIV-1 with an EC50 range from 8.97μM to 0.010μM. Among them, the 6-(3,5-dimethylbenzyl) analogue 5p was identified as the most promising compound (EC50=0.010μM, SI>31,800) associated with moderate activity against the HIV-1 double mutant RT strain K103N+Y181C. The structure–activity relationships of these new congeners were further discussed.
A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants

Shangjiu Hu,Ling Ma,Biao Dong,Qi Shan,Jinming Zhou,Guoning Zhang,Minghua Wang,Shan Cen,Mei Zhu,Juxian Wang,Yucheng Wang

DOI: https://doi.org/10.1016/j.bmc.2022.116760

IF: 3.461

2022-01-01

Bioorganic & Medicinal Chemistry

Abstract:Based upon the preliminary design of enhancing genetic barrier to drug-resistant viral mutants by maximizing hydrogen-bonding or other van der Waals contacts, we have designed, synthesized and biologically evaluated a new class of HIV-1 protease inhibitors with phenol derived P2 ligands and nitro or halogens in P2′ ligands. Results indicate that a majority of inhibitors exhibit robust enzyme inhibitory with IC50 values in picomolar or single digit nanomolar ranges. Among which, compound 17d displays potency with IC50 value of 21 pM and high protease selectivity. Of note, 17d exhibits greater antiviral activity against the DRV-resistant variant than the efficacy against the wild type virus. Furthermore, the molecular modeling studies demonstrate important interactions between 17d and the active sites of both the wild-type and DRV-resistant HIV-1 protease, as well as furnish insights for further optimization of new inhibitors.
Synthesis and Biological Evaluation of Novel Quinoxalinone-Based HIV-1 Reverse Transcriptase Inhibitors

Jie Zhou,Mingyu Ba,Bo Wang,Haibo Zhou,Jianbo Bie,Decai Fu,Yingli Cao,Bailing Xu,Ying Guo

DOI: https://doi.org/10.1039/c3md00337j

2014-01-01

MedChemComm

Abstract:A series of novel N4-substituted thiophen-3-ylsulfonylquinoxalinone derivatives were designed and synthesized by variations of 2- and 5-position of the thiophene ring. All target molecules were tested for their anti-HIV-1 replication activities and compounds 1b and 1d were found to be the most potent inhibitors with an IC50 value at 10−8 mol L−1 level. The preliminary structure–activity relationships were analyzed on the basis of the binding mode of compound 1b predicted by CDOCKER.
Synthesis and Biological Evaluation of Pyridinone Analogues As Novel Potent HIV-1 NNRTIs.

Yuanyuan Cao,Yu Zhang,Shaotong Wu,Quanzhi Yang,Xuefeng Sun,Jianxiong Zhao,Fen Pei,Ying Guo,Chao Tian,Zhili Zhang,Haining Wang,Liying Ma,Junyi Liu,Xiaowei Wang

DOI: https://doi.org/10.1016/j.bmc.2014.11.012

IF: 3.461

2014-01-01

Bioorganic & Medicinal Chemistry

Abstract:A novel 2-pyridinone scaffold was rationally designed and synthesized based on the active anti-HIV agent 1 (LAM-trans) via an efficient method. The biological results revealed that some target compounds inhibited HIV-1 reverse transcriptase in the lower micromolar concentration range (IC50 0.089-0.68 μm). Notably, the most promising compound 25b exhibited extremely potent inhibitory activity against HIV-1 replication with an EC50 value of 0.0563 μM and the viral selectivity index amounted to 3466.8. Molecular modeling studies were performed, and some SARs were rationalized.
Design, Synthesis, and Biological Evaluation of Novel 5-Alkyl-6-adamantylmethylpyrimidin-4(3h)-ones As Hiv-1 Non-Nucleoside Reverse-Transcriptase Inhibitors

Wenxin Li,Boshi Huang,Dongwei Kang,Erik De Clercq,Dirk Daelemans,Christophe Pannecouque,Peng Zhan,Xinyong Liu

DOI: https://doi.org/10.1111/cbdd.12765

2016-01-01

Chemical Biology & Drug Design

Abstract:A series of novel 5-alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones bearing various substituents at the C-2 position of the pyrimidinone ring were synthesized using a facile route and evaluated for their anti-HIV activity in MT-4 cells. The biological results demonstrated that the majority of the newly designed compounds possessed moderate efficiency in inhibiting the replication of the wild-type (WT) HIV-1 strain (IIIB) with EC50 values in the range from 0.10 to 5.39m. Among them, 5b1 and 5b3 proved to be the two most active inhibitors against WT HIV-1 with EC50 values of 0.10 and 0.12m, respectively, which were more active than nevirapine (NVP) in the same assay. In addition, HIV-1 reverse-transcriptase (RT) inhibition assay indicated that the representative compound 5b1 showed affinity to WT HIV-1 RT, and inhibited the activity of RT with an IC50 value superior to the reference drug NVP. Moreover, the preliminary structure-activity relationship (SAR) and the molecular modeling analysis of these new derivatives are also discussed.
Synthesis and Biological Evaluation of a Series of 2-(((5-akly/aryl-1h-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3h)-ones As Potential HIV-1 Inhibitors.

Yumeng Wu,Chengrun Tang,Ruomei Rui,Liumeng Yang,Wei Ding,Jiangyuan Wang,Yiming Li,Christopher C. Lai,Yueping Wang,Ronghua Luo,Weilie Xiao,Hongbing Zhang,Yongtang Zheng,Yanping He

DOI: https://doi.org/10.1016/j.apsb.2019.08.009

IF: 14.903

2019-01-01

Acta Pharmaceutica Sinica B

Abstract:A series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones were synthesized and their anti-HIV-1 activities were evaluated. Most of these compounds were highly active against wild-type (WT) HIV-1 strain (IIIB) with EC50 values in the range of 0.0038-0.4759 mmol/L. Among those compounds, I-11 had an EC50 value of 3.8 nmol/L and SI (selectivity index) of up to 25,468 indicating excellent activity against WT HIV-1. In vitro anti-HIV-1 activity and resistance profile studies suggested that compounds I-11 and I-12 displayed potential anti-HIV-1 activity against laboratory adapted strains and primary isolated strains including different subtypes and tropism strains (EC(50)s range from 4.3 to 63.6 nmol/L and 18.9-219.3 nmol/L, respectively). On the other hand, it was observed that those two compounds were less effective with EC50 values of 2.77 and 4.87 mmol/L for HIV-1A(17) (K103N + Y181C). The activity against reverse transcriptase (RT) was also evaluated for those compounds. Both I-11 and I-12 obtained sub-micromolar IC50 values showing their potential in RT inhibition. The pharmacokinetics examination in rats indicated that compound I-11 has acceptable pharmacokinetic properties and bioavailability. Preliminary structure-activity relationships and molecular modeling studies were also discussed. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety

Mengwei Zhu,Tiantian Fu,Mengyuan You,Junyuan Cao,Hanxi Yang,Xinyao Chen,Qiumeng Zhang,Yechun Xu,Xiangrui Jiang,Leike Zhang,Haixia Su,Yan Zhang,Jingshan Shen

DOI: https://doi.org/10.1016/j.bmc.2023.117316

2023-05-10

Abstract:In this paper, a series of peptidomimetic SARS-CoV-2 3CL protease inhibitors with new P2 and P4 positions were synthesized and evaluated. Among these compounds, 1a and 2b exhibited obvious 3CL pro inhibitory activities with IC 50 of 18.06 nM and 22.42 nM, respectively. 1a and 2b also showed excellent antiviral activities against SARS-CoV-2 in vitro with EC 50 of 313.0 nM and 170.2 nM, respectively, the antiviral activities of 1a and 2b were 2- and 4-fold better than that of nirmatrelvir, respectively. In vitro studies revealed that these two compounds had no significant cytotoxicity. Further metabolic stability tests and pharmacokinetic studies showed that the metabolic stability of 1a and 2b in liver microsomes was significantly improved, and 2b had similar pharmacokinetic parameters to that of nirmatrelvir in mice.

biochemistry & molecular biology,chemistry, medicinal, organic

Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands.

Preliminary SAR and Biological Evaluation of Potent HIV-1 Protease Inhibitors with Pyrimidine Bases As Novel P2 Ligands to Enhance Activity Against DRV-resistant HIV-1 Variants

Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1 ligands

Design, Synthesis, and Biological Evaluation of Novel HIV-1 Protease Inhibitors Containing Pyrrolidine-Derived P2 Ligands to Combat Drug-Resistant Variant

Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C

Design and Biological Evaluation of Novel HIV-1 Protease Inhibitors with Isopropanol As P1′ Ligand to Enhance Binding with S1′ Subsite

Design, Synthesis and Biological Evaluation of HIV-1 Protease Inhibitors with Morpholine Derivatives As P2 Ligands in Combination with Cyclopropyl As P1' Ligand.

Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants

Design and Evaluation of Novel Piperidine HIV-1 Protease Inhibitors with Potency Against DRV-resistant Variants

Design and Synthesis of Potent HIV-1 Protease Inhibitors with (S)-Tetrahydrofuran-tertiary Amine-Acetamide As P2−ligand: Structure−activity Studies and Biological Evaluation

Piperidine Scaffold As the Novel P2-ligands in Cyclopropyl-Containing HIV-1 Protease Inhibitors: Structure-based Design, Synthesis, Biological Evaluation and Docking Study

Design and Biological Evaluation of Cinnamic and Phenylpropionic Amide Derivatives As Novel Dual Inhibitors of HIV-1 Protease and Reverse Transcriptase

Novel HIV-1 Protease Inhibitors with Morpholine As the P2 Ligand to Enhance Activity Against DRV-Resistant Variants

Synthesis and Biological Evaluation of Dihydroquinazoline-2-amines As Potent Non-Nucleoside Reverse Transcriptase Inhibitors of Wild-Type and Mutant HIV-1 Strains.

Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants

Synthesis and Biological Evaluation of Novel Quinoxalinone-Based HIV-1 Reverse Transcriptase Inhibitors

Synthesis and Biological Evaluation of Pyridinone Analogues As Novel Potent HIV-1 NNRTIs.

Design, Synthesis, and Biological Evaluation of Novel 5-Alkyl-6-adamantylmethylpyrimidin-4(3h)-ones As Hiv-1 Non-Nucleoside Reverse-Transcriptase Inhibitors

Synthesis and Biological Evaluation of a Series of 2-(((5-akly/aryl-1h-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3h)-ones As Potential HIV-1 Inhibitors.

Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety